Spruce’s lead product candidate, ... neurodegenerative disorder for which there are no FDA-approved therapies. TA-ERT has received Breakthrough Therapy Designation, Rare Pediatric Disease Designation, Fast Track Designation and Orphan Drug Designation from the FDA, as well as Orphan ... Spruce’s lead product candidate, tralesinidase alfa enzyme replacement therapy (TA-ERT), is in late-stage development for the treatment of mucopolysaccharidoses type IIIB (MPS IIIB), or Sanfilippo Syndrome Type B, a devastating pediatric neurodegenerative disorder for which there are no FDA-approved therapies. TA-ERT has received Breakthrough Therapy Designation, Rare Pediatric Disease Designation, Fast Track Designation and Orphan Drug Designation from the FDA, as well as Orphan Drug Designation in the European Union. The strategic investment reflects a shared commitment among Spruce and two of the leading organizations serving the MPS and Sanfilippo communities to accelerate access to TA-ERT for the treatment of MPS IIIB, a devastating, rapidly progressing neurodegenerative disease that primarily affects children and for which there are no FDA-approved therapies. The Foundations’ and community fundraising efforts led to the initiation of EAP start-up activities earlier this year, including manufacturing of drug product, to accelerate access to children and families impacted by MPS IIIB in advance of potential U.S. The final stage of MPS IIIB is typically marked by severe dementia, loss of motor function, and seizure activity, with patients largely bed-ridden and requiring constant care, requiring feeding tubes for hydration and nutrition, and ultimately leading to death. The estimated life expectancy of individuals with MPS IIIB ranges from 15 to 19 years of age. Currently, there are no FDA-approved therapies for MPS IIIB, and management of the disease consists of limited palliative care to improve quality of life. As both a physician and a parent in this community, I know the urgency families feel as they watch this devastating disease take abilities from their children,” said Cara O’Neill, M.D., Chief Science Officer and Co-Founder of Cure Sanfilippo Foundation. “The encouraging clinical data for TA-ERT offer meaningful hope, and our investment reflects the Foundation’s deep commitment to advancing rigorous science while bringing promising therapies within reach for children who need time-sensitive access.

A recent study published in PubMed explores a rare neurodegenerative disorder characterized by regression, ataxia, and nystagmus in a toddler. This research contributes to the understanding of the clinical presentation and potential underlying mechanisms of this condition.

Spruce’s lead product candidate, ... neurodegenerative disorder for which there are no FDA-approved therapies. TA-ERT has received Breakthrough Therapy Designation, Rare Pediatric Disease Designation, Fast Track Designation and Orphan Drug Designation from the FDA, as well as Orphan ... Spruce’s lead product candidate, tralesinidase alfa enzyme replacement therapy (TA-ERT), is in late-stage development for the treatment of mucopolysaccharidoses type IIIB (MPS IIIB), or Sanfilippo Syndrome Type B, a devastating pediatric neurodegenerative disorder for which there are no FDA-approved therapies. TA-ERT has received Breakthrough Therapy Designation, Rare Pediatric Disease Designation, Fast Track Designation and Orphan Drug Designation from the FDA, as well as Orphan Drug Designation in the European Union. Most recently, as Executive Medical Director, she served as clinical sciences lead for Brineura® (cerliponase alfa), an enzyme replacement therapy for CLN2 disease, a rare pediatric neurodegenerative disorder, leading study closeout and clinical study report development and supporting major regulatory milestones, including an FDA sBLA efficacy supplement approval, an EMA Type II variation approval and an MHRA post-authorization measure approval. Cohen Pfeffer brings more than a decade of biopharmaceutical industry experience spanning clinical development, product portfolio development and medical affairs, with extensive experience in rare disease and a track record of supporting global regulatory approvals for enzyme replacement therapies, including for rare pediatric neurodegenerative disorders. She brings significant experience in rare genetic diseases having spent her career developing and supporting therapies for children with rare genetic and neurodegenerative diseases, including leading clinical sciences for an enzyme replacement therapy for a rare pediatric neurodegenerative disorder,” said Adrian Quartel, M.D., FFPM, Chief Medical Officer of Spruce Biosciences.

Clinical success for gene therapy will require optimizing delivery, specificity, durability, and biomarker readiness. Spinocerebellar ataxias (SCAs), rare neurodegenerative disorders characterized by progressive cerebellar degeneration, cause impaired balance and motor dysfunction. Although most cases are inherited, sporadic forms also occur, and effective disease... Clinical success for gene therapy will require optimizing delivery, specificity, durability, and biomarker readiness. Spinocerebellar ataxias (SCAs), rare neurodegenerative disorders characterized by progressive cerebellar degeneration, cause impaired balance and motor dysfunction. Although most cases are inherited, sporadic forms also occur, and effective disease-modifying therapies remain unavailable despite advances in understanding their genetic and molecular mechanisms. Spinocerebellar ataxias (SCAs), rare neurodegenerative disorders characterized by progressive cerebellar degeneration, cause impaired balance and moto… We propose that SCAs represent a therapeutically stratified disease space in which mutational architecture, disease stage, therapeutic timing, delivery constraints, reversibility, allele specificity, and biomarker readiness collectively determine platform choice. SCAs are a genetically heterogeneous group of inherited neurodegenerative disorders, broadly classified into three major categories: polyglutamine (polyQ) repeat expansion SCAs, noncoding repeat expansion SCAs, and nonrepeat mutation SCAs (Table 1). A major recent advance is that gene- and RNA-based approaches can now be more closely aligned with mutational architecture: toxic mutant transcripts can be suppressed, pathogenic alleles edited, and vulnerable cerebellar neurons supported via adjunctive neuroprotective gene transfer (Figure 2). This reframes SCAs not merely as a heterogeneous group of rare ataxias but as ‘therapeutically structured’ disorders in which mutation type increasingly guides platform selection, target prioritization, and translational strategy. ... Figure 2. Gene therapy strategies for SCAs. A schematic overview of representative gene therapy strategies for correcting or modulating disease-causing genes in SCAs.

The Dutch biotech company uniQure ... disease therapy, AMT‑130, despite a senior FDA official months before telling Reuters on the condition of anonymity the firm's most recent trial lacked necessary data. The drug is the first of its kind, a treatment that has been found to slow the progression of Huntington's disease, a rare, fatal, neurodegenerative disorder. UniQure said that the FDA had informed them that a three-year analysis from an earlier stage clinical trial would ... The Dutch biotech company uniQure said this week that regulators will now allow it to go after an accelerated approval for its Huntington's disease therapy, AMT‑130, despite a senior FDA official months before telling Reuters on the condition of anonymity the firm's most recent trial lacked necessary data. The drug is the first of its kind, a treatment that has been found to slow the progression of Huntington's disease, a rare, fatal, neurodegenerative disorder. UniQure said that the FDA had informed them that a three-year analysis from an earlier stage clinical trial would be acceptable as the primary basis of a Biologics License Application (BLA), needed for the accelerated approval of its closely-watched drug. The FDA has changed its stance on a rare disease therapy, giving the manufacturer the green light to seek approval. The treatment is delivered through a one-time surgical procedure directly into the brain, and early clinical data suggest patients receiving higher doses experienced significantly slower decline compared with expected disease progression. If approved, AMT‑130 could become the first treatment to alter the course of Huntington’s disease, representing a major milestone in gene therapy and rare disease medicine. The FDA had previously demanded uniQure run an entirely new clinical trial involving a controversial "sham surgery" control, which would have required some patients to undergo invasive procedures without receiving the active treatment. The HHS told Newsweek that the FDA has agreed with uniQure on "a path for submission of a marketing application and accelerated approval of the therapy based on the existing clinical data," and that the "accelerated approval pathway is designed to allow earlier approval of drugs that treat serious conditions to address an unmet medical need."